Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic neuropathy worldwide, with a prevalence ranging from ∼1 to 9 cases per 100 000.1–6 CIDP typically ...

Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase III drugs for Chronic ...

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William ...

Batoclimab is under clinical development by Immunovant and currently in Phase II for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase II drugs for Chronic ...

Pregnancy largely affects disease activity and clinical course in women with immune-mediated neurological disorders. Chronic inflammatory demyelinating polyneuropathy (CIDP) is rare but the most ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) ...

Because it generally affects multiple joints, it's often described as an inflammatory polyarthropathy. Is inflammatory polyarthropathy chronic? Not always. How long it lasts depends on the illness ...

Chronic inflammation refers to a prolonged inflammatory response that involves a progressive change in the type of cells present at the site of inflammation. It is characterized by the ...